NVAX (Novavax) Other Current Liabilities: $135.5 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NVAX Novavax Inc NVAX
42 GF Score
Price $7.86
GF Value $3.26
Valuation Significantly Overvalued
! 5 Warning Signs
View Full Analysis

What is Novavax Other Current Liabilities?

Novavax NVAX -1.13% 42 Other Current Liabilities is $135.5 Mil as of Jun. 2026. GuruFocus rates NVAX with a GF Score™ of 42/100 and a GF Value™ of $3.26 (Significantly Overvalued). The stock has 5 warning signs investors should review.

Novavax's other current liabilities for the quarter that ended in Jun. 2026 was $135.5 Mil.

Novavax's quarterly other current liabilities declined from Dec. 2025 ($236.6 Mil) to Mar. 2026 ($132.4 Mil) but then increased from Mar. 2026 ($132.4 Mil) to Jun. 2026 ($135.5 Mil).

Novavax's annual other current liabilities declined from Dec. 2023 ($917.4 Mil) to Dec. 2024 ($279.9 Mil) and declined from Dec. 2024 ($279.9 Mil) to Dec. 2025 ($236.6 Mil).

Novavax Other Current Liabilities Related Terms

Novavax Other Current Liabilities Historical Data

* Premium members only.

The historical data trend for Novavax's Other Current Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Novavax Other Current Liabilities Chart

Novavax Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Current Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 74.48 982.62 917.36 279.95 236.62

Novavax Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Other Current Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 132.53 189.77 236.62 132.45 135.53
NVAX
42GF Score
Novavax Inc NVAX
Other Current Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Novavax Other Current Liabilities Calculation

The liability a company needs to pay in the next 12 months, but not assigned to Accounts Payable or Debt. For instance, Wal-Mart (WMT) has accrued wages, salaries, valuation, bonuses, insurance liabilities, accrued tax etc. These are all included in other current liabilities.

What does a Other Current Liabilities of $135.5 Mil mean?
Novavax (NVAX) has a Other Current Liabilities of $135.5 Mil as of Jun. 2026. Other current liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Novavax.
Is Novavax's Other Current Liabilities too high?
Novavax's current Other Current Liabilities is $135.5 Mil. Overall, Novavax has a GF Score™ of 42/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Novavax's Other Current Liabilities compare to JBIO and AVLN?
Novavax's Other Current Liabilities of $135.5 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Liabilities for a Biotechnology company?
A good Other Current Liabilities depends on the Biotechnology industry context. However, Other Current Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Liabilities mean?
A high Other Current Liabilities can signal that a stock is expensive relative to its fundamentals. Other current liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Novavax. Novavax's current Other Current Liabilities is $135.5 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Novavax stock overvalued right now?
Based on GuruFocus' analysis, Novavax (NVAX) is currently considered Significantly Overvalued. The stock's GF Value™ is $3.26, compared to a current price of $7.86 — trading 141.1% above its estimated fair value. The current Other Current Liabilities is $135.5 Mil. Novavax's overall GF Score™ is 42/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Liabilities calculated?
Other Current Liabilities is calculated from a company's financial statements. For Novavax (NVAX), the current Other Current Liabilities is $135.5 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Novavax (NVAX) Overvalued in 2026?

Based on GuruFocus' analysis, Novavax stock appears to be overvalued. The current stock price of $7.86 is trading 141.1% above its estimated GF Value™ of $3.26. GuruFocus considers Novavax to be Significantly Overvalued.

Key valuation signals for NVAX:

  • Other Current Liabilities: $135.5 Mil
  • GF Value™: $3.26 vs. price of $7.86 (141.1% above fair value)
  • GF Score™: 42/100 with 5 warning signs

No single metric tells the full story. See the NVAX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Novavax Business Description

Address 21 Firstfield Road, Gaithersburg, MD, USA, 20878
Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. It works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The company manages its business as one operating segment, an in-house early-stage R&D business to build a pipeline of high-value assets using its technology along with seeking to enter into partnerships to drive value creation for its assets.
42GF Score

Get the complete analysis for NVAX

Other Current Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$7.86
Price
$3.26
GF Value